TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Mobilization and collection of hematopoietic stem cells (HSCs) using G-CSF at least 6 weeks but less than 6 months prior to protocol enrollment.~2. Ages greater than or equal to 18 years and less than or equal to 55 years.~3. Normal liver and renal function, normal CBC, normal ECG, normal blood pressure including adequately medically controlled idiopathic arterial hypertension, no other contraindications to mobilized peripheral blood stem cell donation according to WMDA criteria and relevant SOPs at the study site defining additional exclusion criteria for stem cell donation.~4. Subject must be eligible for normal blood donation according to requirements for IDMs as laid out by national law for blood donors.~5. Ability to comprehend the investigational nature of the study and provide informed consent.~Exclusion Criteria:~1. Active infection or history of recurrent infection- hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV and HTLV-1.~2. History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous.~3. History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin.~4. History of any hematologic disorders including thromboembolic disease.~5. History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias OR related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention OR treatment or a Framingham coronary disease risk prediction score of greater than 10% 10 year coronary heart disease (CHD) risk.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- POL6326 (Type: EXPERIMENTAL): 2-hour single intravenous infusion doses of POL6326

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Disc Resorption in Lumbar and Cervical Disc Herniation Patients Receiving Integrative Korean Medicine Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Lumbar and/or cervical disc herniation patients with baseline MRI and follow-up results after receiving treatment at Jaseng Hospital of Korean Medicine visiting between February 2012 and December 2015.~* Participants giving informed written consent to use of medical records for academic means.~Exclusion Criteria:~* Participants refusing to participate in study or to respond to phone interview.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumbar/cervical disc herniation group (Type: None): Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has signed an informed consent form before the oocyte retrieval~* The patient is undergoing oocyte retrieval with local anaesthesia~* The patient can speak and understand Swedish~Exclusion Criteria:~* The patient has previously participated in Vitrolife-needle-01 study~* The patient has a body mass index ≥35~* Other contra indicator for oocyte retrieval

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thin Follicle Aspiration Needle (Type: EXPERIMENTAL): Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
- Standard Follicle Aspiration Needle (Type: ACTIVE_COMPARATOR): Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects of non-childbearing potential and healthy male subjects (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).~* Body Mass Index (BMI) of 17.5 to 32.0 kg/m2; and a total body weight \>50kg (110 lbs).~Exclusion Criteria:~* Evidence or history of clinically significant infectious, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, autoimmune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).~* Previous exposure to a monoclonal antibody, or current use of other biologics.~* History of hypersensitivity reaction to inactive components of the study drugs or any murine proteins or anaphylactic reactions to therapeutic drugs.~* History of tuberculosis (TB) or a positive latent TB test at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A = PF-06438179 (Type: EXPERIMENTAL): None
- B = Infliximab-EU (Type: ACTIVE_COMPARATOR): None
- C = Infliximab-US (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previous stroke or TIA~Exclusion Criteria:~* coronary heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BАbykids Spray In Common Cold

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Male/Female subjects \>2 and ≤6-year-old~* 2. Acute infectious rhinitis/rhinosinusitis for ≤48h before trial entry~* 3. Patient presenting with fever ≥ 37.5 °C at screening~* 4. Subjects with nasal congestion (blocked / stuffy nose) rated at least as moderate on the Acute Rhinitis Symptoms Severity Questionnaire, based on evaluation by the investigator~* 5. Subjects showing at least moderate grade for at least one of the following additional signs of acute rhinitis: runny nose, nasal crust (dry mucus), sneezing and cough~* 6. Written consent obtained from parent/legal guardians~Exclusion Criteria:~* 1. Known hypersensitivity/allergy to any component of the test device~* 2. Medical history that is considered by the investigator as a reason for non-inclusion,~* 3. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps~* 4. History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores~* 5. Antibiotic intake within 2 weeks before screening~* 6. Systemic corticosteroids within 4 weeks before screening~* 7. Chronic decongestant use~* 8. Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence ARSSQ score at screening (NSAID, nasal decongestants, cough medicines)

- Gender: ALL
- Minimum Age: 25 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Healsea Babykids (Type: EXPERIMENTAL): Healsea® Babykids, nasal spray indistinguishable from the comparator. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).
- Placebo (Type: PLACEBO_COMPARATOR): The comparator is a saline isotonic nasal spray considered as inert Placebo i.e., neutral for the nasal mucosa.~Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III HER-2 positive breast cancer~* Receiving adjuvant therapy with trastuzumab~* Provide informed consent~* Exhibit LV dysfunction as evidenced by either~  * LVEF between 40% and the lower limit for normal (i.e. \<54% in women or \< 52% in men18), or~ * LVEF within normal limits (i.e. ≥54% in women or ≥52% in men) and NYHA class II heart failure symptoms within the past year, or~ * A fall in LVEF of ≥15% from baseline~Exclusion Criteria:~Patients will not be eligible for SCHOLAR if they have any of the following:~* NYHA class III or IV heart failure~* Systolic blood pressure \<90mmHg~* Current use of both ACE-I/angiotensin receptor blocker and beta-blocker~* Contra-indication to both ACE-I/angiotensin receptor blocker and beta-blocker

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heart failure (Type: EXPERIMENTAL): Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients can be included if ALL the following criteria are met:~  1.Newly diagnosed with IPF within 6 months based upon recent ATS/ERS/JRS/ALAT IPF guideline (Ref 1, Raghu G, et al. 2011).~* Exclusion of other known causes of ILD (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity).~* Assessment of IPF based on HRCT or HRCT and surgical lung biopsy, if available. 2.Patient ≥ 20 years of age 3.Written informed consent prior to participation 4.Patients with further follow-up possible with participating physician during planned study period 5.Ability to read and write in the local language~Exclusion Criteria:~* Patients should not be included if ANY of the following criteria is met:~  1. Lung transplantation expected within next 6 months.~ 2. Inclusion in ongoing clinical trials.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with idiopathic pulmonary fibrosis (IPF) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrapleural Gene Transfer for Pleural Mesothelioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of progressive disease after standard first line treatment of mesothelioma; OR patient has refused standard first line treatment of mesothelioma~* evaluable disease~* No radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic agents within 14 days prior to infusion of the IFN-α vector~* Must have a pleural space involved with tumor accessible for pleural catheter insertion~* FEV1\> 1 liter or 40% of predicted value~* Must have an anti-adenoviral neutralizing antibody titer equal to or less than 1:1000. This will be measured by the Penn Vector Core~Exclusion Criteria:~* Presence of HIV or Hepatitis B infection~* Use of concurrent systemic steroids, immunosuppressives, or any other medications that can directly or indirectly suppress the immune system~* Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependence, significant chronic obstructive pulmonary disease (COPD), end stage liver or renal disease~* Presence of untreated brain metastases~* Prior bone marrow or stem cell transplants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 (Type: EXPERIMENTAL): None
- Dose Level 2 (Type: EXPERIMENTAL): This is a dose de escalation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Body mass index (BMI) greater than or equal to 30.0 kg/m\^2~* New York Heart Association (NYHA) Class II-IV~* Left ventricular ejection fraction (LVEF) greater than or equal to 45% at screening~* Diagnosed with T2D greater than or equal to 90 days prior to the day of screening~* HbA1c of below or equal to 10.0% as measured at the screening visit~Exclusion Criteria:~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 2.4 mg once weekly (OW) (Type: EXPERIMENTAL): Participants will receive semaglutide injections for 52 weeks.
- Semaglutide placebo OW (Type: PLACEBO_COMPARATOR): Participants will receive semaglutide placebo injections for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PCV13 in Non-pregnant Papua New Guinean Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Non-pregnant~* 18-45 years old~Exclusion Criteria:~* Known hypersensitivity to any vaccine component~* Known/suspected to be immunocompromised~* Receipt of corticosteroids ≤30 days before~* Pregnant (pregnancy tests will be performed)~* Not being well at the time of vaccination~* Plan to travel out of the area in the month post-vaccination

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: None

Study Arms:
- Women of childbearing age (Type: None): Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* history of grass pollen induced allergic rhinoconjunctivitis~* positive skin prick test~Exclusion Criteria:~* uncontrolled severe bronchial asthma~* previous treatment with immunotherapy within the previous 5 years~* contraindication for specific immunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Allergy vaccination (Type: ACTIVE_COMPARATOR): Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
- Subcutaneous injections (Type: PLACEBO_COMPARATOR): Placebo injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Standard Versus High Dose Inactivated Influenza Vaccine in RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of seropositive RA (rheumatoid factor (RF) and/or anti-CCP antibody positive) based on the 2010 ACR-EULAR criteria.~2. At least 6 months of treatment including anti-TNF agents, abatacept, rituximab (dose received within the previous 6 months) and/or methotrexate.~3. Informed consent form signed and dated.~4. Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~1. Vaccination against influenza in the 6 months preceding the trial vaccination.~2. Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components, or a history of a life-threatening reaction to TIV or to a vaccine containing any of the same substances.~3. History of Guillain-Barré syndrome within six weeks of a previous influenza vaccination.~4. Dementia or any other cognitive condition that could interfere with the trial procedures.~5. Thrombocytopenia or bleeding disorder contraindicating IM vaccination (according to treating rheumatologist).~6. Current alcohol abuse or drug addiction.~7. Moderate or severe acute illness with or without fever. If this exists, vaccination will be deferred until the individual has been medically stable and/or afebrile for at least 24 hours.~8. Signs and symptoms of an acute infectious respiratory illness. If this exists, vaccination will be deferred until the symptoms resolve.~9. Pregnant women (the rationale for excluding this group is not their lack of indication for vaccination but the changes of maternal immune responses during pregnancy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose influenza vaccine (Type: ACTIVE_COMPARATOR): Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
- High dose influenza vaccine (Type: ACTIVE_COMPARATOR): Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient chronic olfactory dysfunction lasting more than 6 months after an infection of COVID-19~Exclusion Criteria:~* Patient under 18 years old~* Patient with blood disorder~* Blood thinner user~* Patient with abnormal findings on nasal endoscopy (e.g., polyposis, rhinosinusitis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- control group (Type: OTHER): Patient underwent simple olfactive training for one month.
- PRP injected group (Type: EXPERIMENTAL): Patient had one injection in each olfactory cleft.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete